Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Gains from Investment Securities (2020 - 2022)

Historic Gains from Investment Securities for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q3 2022 value amounting to $3.7 million.

  • Atea Pharmaceuticals' Gains from Investment Securities rose 873.83% to $3.7 million in Q3 2022 from the same period last year, while for Sep 2022 it was $3.7 million, marking a year-over-year increase of 873.83%. This contributed to the annual value of $2.9 million for FY2022, which is 7206.42% down from last year.
  • Latest data reveals that Atea Pharmaceuticals reported Gains from Investment Securities of $3.7 million as of Q3 2022, which was up 873.83% from $3.4 million recorded in Q2 2022.
  • Over the past 5 years, Atea Pharmaceuticals' Gains from Investment Securities peaked at $10.5 million during Q4 2021, and registered a low of $293861.0 during Q2 2020.
  • In the last 3 years, Atea Pharmaceuticals' Gains from Investment Securities had a median value of $3.4 million in 2022 and averaged $3.7 million.
  • The largest annual percentage gain for Atea Pharmaceuticals' Gains from Investment Securities in the last 5 years was 100062.07% (2021), contrasted with its biggest fall of 92.21% (2021).
  • Quarter analysis of 3 years shows Atea Pharmaceuticals' Gains from Investment Securities stood at $3.4 million in 2020, then soared by 208.52% to $10.5 million in 2021, then plummeted by 64.43% to $3.7 million in 2022.
  • Its Gains from Investment Securities stands at $3.7 million for Q3 2022, versus $3.4 million for Q2 2022 and $2.9 million for Q1 2022.